Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells.
Peptostreptococcus magnus strain 312 (10(6) to 10(8)/ml), which synthesizes a protein capable of binding to kappa L chains of human Ig (protein L), stimulated the release of histamine from human basophils in vitro. P. magnus strain 644, which does not synthesize protein L, did not induce histamine secretion. Soluble protein L (3 x 10(-2) to 3 micrograms/ml) induced histamine release from human basophils. The characteristics of the release reaction were similar to those of rabbit IgG anti-Fc fragment of human IgE (anti-IgE): it was Ca2(+)- and temperature-dependent, optimal release occurring at 37 degrees C in the presence of 1.0 mM extracellular Ca2+. There was an excellent correlation (r = 0.82; p less than 0.001) between the maximal percent histamine release induced by protein L and that induced by anti-IgE, as well as between protein L and protein A from Staphylococcus aureus (r = 0.52; p less than 0.01). Preincubation of basophils with either protein L or anti-IgE resulted in complete cross-desensitization to a subsequent challenge with the heterologous stimulus. IgE purified from myeloma patients PS and PP (lambda-chains) blocked anti-IgE-induced histamine release but failed to block the histamine releasing activity of protein L. In contrast, IgE purified from myeloma patient ADZ (kappa-chains) blocked both anti-IgE- and protein L-induced releases, whereas human polyclonal IgG selectively blocked protein L-induced secretion. Protein L acted as a complete secretagogue, i.e., it activated basophils to release sulfidopeptide leukotriene C4 as well as histamine. Protein L (10(-1) to 3 micrograms/ml) also induced the release of preformed (histamine) and de novo synthesized mediators (leukotriene C4 and/or PGD2) from mast cells isolated from lung parenchyma and skin tissues. Intradermal injections of protein L (0.01 to 10 micrograms/ml) in nonallergic subjects caused a dose-dependent wheal-and-flare reaction. Protein L activates human basophils and mast cells in vitro and in vivo presumably by interacting with kappa L chains of the IgE isotype.
Patella
V
V
Department of Medicine, University of Naples Federico II, Italy.
Casolaro
V
V
Björck
L
L
Marone
G
G
D000944:Antigens, Differentiation, B-Lymphocyte / Q000502:physiology; D001426:Bacterial Proteins / Q000276:immunology* / Q000378:metabolism*; D001491:Basophils / Q000276:immunology*; D006636:Histamine Release; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000378:metabolism*; D066298:In Vitro Techniques; D008168:Lung / Q000166:cytology; D008407:Mast Cells / Q000276:immunology*; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D010462:Peptostreptococcus / Q000276:immunology*; D011961:Receptors, Fc / Q000502:physiology; D017455:Receptors, IgE; D013189:SRS-A / Q000096:biosynthesis; D012867:Skin / Q000166:cytology; D013205:Staphylococcal Protein A / Q000494:pharmacology
D000944:Antigens, Differentiation, B-Lymphocyte; D001426:Bacterial Proteins; C029152:G-substrate; C055047:Ig L-binding protein, Peptostreptococcus; D007145:Immunoglobulin kappa-Chains; D009419:Nerve Tissue Proteins; D011961:Receptors, Fc; D017455:Receptors, IgE; D013189:SRS-A; D013205:Staphylococcal Protein A